Drug
TAK-981
TAK-981 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 40.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
40.0%
Based on 2 completed trials
Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
3(60%)
Phase Distribution
Ph early_phase_1
1
20%
Ph phase_1
4
80%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
4(80.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
40.0%
2 of 5 finished
Non-Completion Rate
60.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(3)
Detailed Status
Terminated3
Completed2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (20.0%)
Phase 14 (80.0%)
Trials by Status
completed240%
terminated360%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
NCT04381650
terminatedphase_1
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
NCT03648372
terminatedphase_1
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04776018
terminatedphase_1
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT04074330
completedearly_phase_1
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
NCT04065555
Clinical Trials (5)
Showing 5 of 5 trials
NCT04381650Phase 1
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
NCT03648372Phase 1
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
NCT04776018Phase 1
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04074330Phase 1
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT04065555Early Phase 1
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5